当前位置: X-MOL 学术medRxiv. Infect. Dis. › 论文详情
Effectiveness of Ivermectin as add-on Therapy in COVID-19 Management (Pilot Trial)
medRxiv - Infectious Diseases Pub Date : 2020-07-08 , DOI: 10.1101/2020.07.07.20145979
Faiq I. Gorial; Sabeeh Mashhadani; Hend M Sayaly; Basim Dhawi Dakhil; Marwan M AlMashhadani; Adnan M Aljabory; , Hassan M Abbas; Mohammed Ghanim; Jawad I Rasheed

Background: To date no effective therapy has been demonstrated for COVID-19. In vitro, studies indicated that ivermectin (IVM) has antiviral effect. Objectives: To assess the effectiveness of ivermectin (IVM) as add-on therapy to hydroxychloroquine (HCQ) and azithromycin (AZT) in treatment of COVID-19. Methods: This Pilot clinical trial conducted on hospitalized adult patients with mild to moderate COVID-19 diagnosed according to WHO interim guidance. Sixteen Patients received a single dose of IVM 200Mcg /kg on admission day as add on therapy to hydroxychloroquine ( HCQ)and Azithromycin (AZT) and were compared with 71 controls received HCQ and AZT matched in age, gender, clinical features, and comorbidities. The primary outcome was percentage of cured patients, defined as symptoms free to be discharged from the hospital and 2 consecutive negative PCR test from nasopharyngeal swabs at least 24 hours apart. The secondary outcomes were time to cure in both groups and evaluated by measuring time from admission of the patient to the hospital till discharge. Results: Of 87 patients included in the study,t he mean age ± SD (range) of patients in the IVM group was similar to controls [44.87 ± 10.64 (28-60) vs 45.23 ± 18.47 (8-80) years, p=0.78] Majority of patients in both groups were male but statistically not significant [11(69%) versus 52 (73%), with male: female ratio 2.21 versus 2.7-, p=0.72) All the patients of IVM group were cured compared with the controls [ 16 (100 %) vs 69 (97.2 %)]. Two patients died in the controls. The mean time to stay in the hospital was significantly lower in IVM group compared with the controls (7.62 ±2.75 versus 13.22 ±.90 days, p=0.00005, effect size= 0.82). No adverse events were observed Conclusions : Add-on use of IVM to HCQ and AZT had better effectiveness, shorter hospital stay, and relatively safe compared with controls. however, a larger prospective study with longer follow up may be needed to validate these results.
更新日期:2020-07-08

 

全部期刊列表>>
欢迎访问IOP中国网站
自然职场线上招聘会
GIANT
产业、创新与基础设施
自然科研线上培训服务
材料学研究精选
胸腔和胸部成像专题
屿渡论文,编辑服务
何川
苏昭铭
陈刚
姜涛
李闯创
李刚
北大
隐藏1h前已浏览文章
课题组网站
新版X-MOL期刊搜索和高级搜索功能介绍
ACS材料视界
天合科研
x-mol收录
上海纽约大学
陈芬儿
厦门大学
何振宇
史大永
吉林大学
卓春祥
张昊
杨中悦
试剂库存
down
wechat
bug